Published in Cancer Weekly, March 24th, 1997
For this trial, more than 200 patients have been enrolled in 15 participating trial centers across Canada. A similar trial of the same magnitude has been taking place in Europe.
"The AltaRex Ovarex program is another excellent example of basic research moving from the lab to the marketplace," commented Dr. Matt Spence, AHFMR. Dr. Antoine (Tony) Noujaim, AltaRex, said,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.